AGTR1 and Alzheimer disease: Our recent findings and some animal and clinical studies have demonstrated that AT1 receptor blockers (ARBs) can reduce cerebral ischemic damage [22, 23], improve cognitive decline, and may be associated with a reduced risk of dementia in subjects with or without AD [24–26].